Participated in Accipiter Bio's $10.5M seed round top-up to advance AI-designed protein therapeutics.
Accipiter Biosciences designs and develops de novo protein therapies — unbound by natural limitations — to address the world’s most complex diseases
Accipiter Biosciences designs and develops de novo protein therapies — unbound by natural limitations — to address the world’s most complex diseases. Their single-agent biologics are custom-engineered to engage multiple pathways without the limitations of traditional combination therapies.